References
- Jain R, Ward-Harley K A. Tumour blood-flow characteristics, modification and role in hyperthermia. IEEE Trans Sonics Ultrason 1984; 31: 504–26
- Voorhees W D, Babbs C F. Hydralazine-enhanced selective heating of transmissible venereal tumour implants in dogs. Eur J Clin Oncol 1982; 18: 1027–33
- Brown J M. Exploitation of bioreductive agents with vasoactive drugs. Radiation research, J M Fielden, et al. Taylor and Francis Ltd., London 1987; 719–24
- Chaplin D J, Acker B. Potentiation of RSU 1069 tumour cytotoxicity by hydralazine: a new approach to selective therapy. Int J Radiat Oncol Biol Phys 1987; 13: 579–86
- Stratford I J, Godden J, Howells P, Embling P, Adams G E. Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours. Radiation research, J M Fielden, et al. Taylor and Francis Ltd., London 1987; 737–42
- Okunieff P., Kallinowski F, Vaupel P, Neuringer L. Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy. J Natl Cancer Inst 1989; 80: 745–50
- Tozer G M, Maxwell R J, Griffiths J R, Proctor E, Busza A. Modification of the blood flow and the energy metabolism of transplanted rat tumours using antihypertensive agents. Br J Radiol 1990; 63: 321
- Rowell N P, Flower M A, McCready V R, Cronin B, Horwich A. The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiother Oncol 1990; 18: 283–92
- Burney I A, Maxwell R J, Griffiths J R, Filed S B. The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours. Br J Cancer 1991; 64: 683–8
- Field S B, Needham S, Burney I A, Maxwell R J, Coggle J, Griffiths J R. Differences in vascular response between primary and transplanted tumours. Br J Cancer 1991; 63: 723–6
- Wood P J, Stratford I J, Sansom J M, Cattanach B M, Quinney R M, Adams G E. The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 1992; 22: 473–6
- Kim S-G, Ackerman J JH. Quantitative determination of tumour blood flow and perfusion via deuterium nuclear magnetic resonance spectroscopy. Cancer Res 1988; 48: 3449–53
- Matiello J, Evelhoch J L. Relative volume-average murine tumor blood flow measurement via deuterium nuclear magnetic resonance spectroscopy. Magn Reson Med 1991; 18: 320–34
- Bradley J K, Counsell C JR, Bremner J CM, Sansom J M, Adams G E. The accuracy and reproducibility of measuring blood flow in murine tumours by the D2O uptake and clearance techniques. NMR Biomed 1993; 7: 141–8
- Eskey C J, Wolmark N, McDowell C L, Domach M M, Jain R K. Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. J Natl Cancer Inst 1994; 86: 293–9